Cargando…

Vasculogenic mimicry, a negative indicator for progression free survival of lung adenocarcinoma irrespective of first line treatment and epithelial growth factor receptor mutation status

BACKGROUND: Vascular mimicry (VM) was associated with the prognosis of cancers. The aim of the study was to explore the association between VM and anticancer therapy response in patients with lung adenocarcinoma. METHODS: This was a single-center retrospective study of patients with lung adenocarcin...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Xuejun, You, Jijun, Ding, Haibing, Zhang, Zhisheng, Cui, Lin, Shen, Xiaomei, Bian, Xiaoxia, Liu, Yanqing, Chen, Jue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7866877/
https://www.ncbi.nlm.nih.gov/pubmed/33549061
http://dx.doi.org/10.1186/s12885-021-07863-z
_version_ 1783648175351922688
author He, Xuejun
You, Jijun
Ding, Haibing
Zhang, Zhisheng
Cui, Lin
Shen, Xiaomei
Bian, Xiaoxia
Liu, Yanqing
Chen, Jue
author_facet He, Xuejun
You, Jijun
Ding, Haibing
Zhang, Zhisheng
Cui, Lin
Shen, Xiaomei
Bian, Xiaoxia
Liu, Yanqing
Chen, Jue
author_sort He, Xuejun
collection PubMed
description BACKGROUND: Vascular mimicry (VM) was associated with the prognosis of cancers. The aim of the study was to explore the association between VM and anticancer therapy response in patients with lung adenocarcinoma. METHODS: This was a single-center retrospective study of patients with lung adenocarcinoma between March 1st, 2013, to April 1st, 2019, at the Second People’s Hospital of Taizhou City. All included patients were divided into the VM and no-VM groups according to whether VM was observed or not in the specimen. Vessels with positive PAS and negative CD34 staining were confirmed as VM. The main outcome was progression-free survival (PFS). RESULTS: Sixty-six (50.4%) patients were male. Eighty-one patients received chemotherapy as the first-line treatment, and 50 patients received TKIs. Forty-five (34.4%) patients were confirmed with VM. There was no difference regarding the first-line treatment between the VM and no-VM groups (P = 0.285). The 86 patients without VM had a median PFS of 279 (range, 90–1095) days, and 45 patients with VM had a median PFS of 167 (range, 90–369) days (P < 0.001). T stage (hazard ratio (HR) = 1.37, 95% confidence interval (CI): 1.10–1.71), N stage (HR = 1.43, 95%CI: 1.09–1.86), M stage (HR = 2.85, 95%CI: 1.76–4.61), differentiation (HR = 1.85, 95%CI: 1.29–2.65), therapy (HR = 0.32, 95%CI: 0.21–0.49), VM (HR = 2.12, 95%CI: 1.33–3.37), and ECOG (HR = 1.41, 95%CI: 1.09–1.84) were independently associated with PFS. CONCLUSION: The benefits of first-line TKIs for NSCLC with EGFR mutation are possibly better than those of platinum-based regimens in patients without VM, but there is no difference in the benefit of chemotherapy or target therapy for VM-positive NSCLC harboring EGFR mutations.
format Online
Article
Text
id pubmed-7866877
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-78668772021-02-08 Vasculogenic mimicry, a negative indicator for progression free survival of lung adenocarcinoma irrespective of first line treatment and epithelial growth factor receptor mutation status He, Xuejun You, Jijun Ding, Haibing Zhang, Zhisheng Cui, Lin Shen, Xiaomei Bian, Xiaoxia Liu, Yanqing Chen, Jue BMC Cancer Research Article BACKGROUND: Vascular mimicry (VM) was associated with the prognosis of cancers. The aim of the study was to explore the association between VM and anticancer therapy response in patients with lung adenocarcinoma. METHODS: This was a single-center retrospective study of patients with lung adenocarcinoma between March 1st, 2013, to April 1st, 2019, at the Second People’s Hospital of Taizhou City. All included patients were divided into the VM and no-VM groups according to whether VM was observed or not in the specimen. Vessels with positive PAS and negative CD34 staining were confirmed as VM. The main outcome was progression-free survival (PFS). RESULTS: Sixty-six (50.4%) patients were male. Eighty-one patients received chemotherapy as the first-line treatment, and 50 patients received TKIs. Forty-five (34.4%) patients were confirmed with VM. There was no difference regarding the first-line treatment between the VM and no-VM groups (P = 0.285). The 86 patients without VM had a median PFS of 279 (range, 90–1095) days, and 45 patients with VM had a median PFS of 167 (range, 90–369) days (P < 0.001). T stage (hazard ratio (HR) = 1.37, 95% confidence interval (CI): 1.10–1.71), N stage (HR = 1.43, 95%CI: 1.09–1.86), M stage (HR = 2.85, 95%CI: 1.76–4.61), differentiation (HR = 1.85, 95%CI: 1.29–2.65), therapy (HR = 0.32, 95%CI: 0.21–0.49), VM (HR = 2.12, 95%CI: 1.33–3.37), and ECOG (HR = 1.41, 95%CI: 1.09–1.84) were independently associated with PFS. CONCLUSION: The benefits of first-line TKIs for NSCLC with EGFR mutation are possibly better than those of platinum-based regimens in patients without VM, but there is no difference in the benefit of chemotherapy or target therapy for VM-positive NSCLC harboring EGFR mutations. BioMed Central 2021-02-06 /pmc/articles/PMC7866877/ /pubmed/33549061 http://dx.doi.org/10.1186/s12885-021-07863-z Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
He, Xuejun
You, Jijun
Ding, Haibing
Zhang, Zhisheng
Cui, Lin
Shen, Xiaomei
Bian, Xiaoxia
Liu, Yanqing
Chen, Jue
Vasculogenic mimicry, a negative indicator for progression free survival of lung adenocarcinoma irrespective of first line treatment and epithelial growth factor receptor mutation status
title Vasculogenic mimicry, a negative indicator for progression free survival of lung adenocarcinoma irrespective of first line treatment and epithelial growth factor receptor mutation status
title_full Vasculogenic mimicry, a negative indicator for progression free survival of lung adenocarcinoma irrespective of first line treatment and epithelial growth factor receptor mutation status
title_fullStr Vasculogenic mimicry, a negative indicator for progression free survival of lung adenocarcinoma irrespective of first line treatment and epithelial growth factor receptor mutation status
title_full_unstemmed Vasculogenic mimicry, a negative indicator for progression free survival of lung adenocarcinoma irrespective of first line treatment and epithelial growth factor receptor mutation status
title_short Vasculogenic mimicry, a negative indicator for progression free survival of lung adenocarcinoma irrespective of first line treatment and epithelial growth factor receptor mutation status
title_sort vasculogenic mimicry, a negative indicator for progression free survival of lung adenocarcinoma irrespective of first line treatment and epithelial growth factor receptor mutation status
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7866877/
https://www.ncbi.nlm.nih.gov/pubmed/33549061
http://dx.doi.org/10.1186/s12885-021-07863-z
work_keys_str_mv AT hexuejun vasculogenicmimicryanegativeindicatorforprogressionfreesurvivaloflungadenocarcinomairrespectiveoffirstlinetreatmentandepithelialgrowthfactorreceptormutationstatus
AT youjijun vasculogenicmimicryanegativeindicatorforprogressionfreesurvivaloflungadenocarcinomairrespectiveoffirstlinetreatmentandepithelialgrowthfactorreceptormutationstatus
AT dinghaibing vasculogenicmimicryanegativeindicatorforprogressionfreesurvivaloflungadenocarcinomairrespectiveoffirstlinetreatmentandepithelialgrowthfactorreceptormutationstatus
AT zhangzhisheng vasculogenicmimicryanegativeindicatorforprogressionfreesurvivaloflungadenocarcinomairrespectiveoffirstlinetreatmentandepithelialgrowthfactorreceptormutationstatus
AT cuilin vasculogenicmimicryanegativeindicatorforprogressionfreesurvivaloflungadenocarcinomairrespectiveoffirstlinetreatmentandepithelialgrowthfactorreceptormutationstatus
AT shenxiaomei vasculogenicmimicryanegativeindicatorforprogressionfreesurvivaloflungadenocarcinomairrespectiveoffirstlinetreatmentandepithelialgrowthfactorreceptormutationstatus
AT bianxiaoxia vasculogenicmimicryanegativeindicatorforprogressionfreesurvivaloflungadenocarcinomairrespectiveoffirstlinetreatmentandepithelialgrowthfactorreceptormutationstatus
AT liuyanqing vasculogenicmimicryanegativeindicatorforprogressionfreesurvivaloflungadenocarcinomairrespectiveoffirstlinetreatmentandepithelialgrowthfactorreceptormutationstatus
AT chenjue vasculogenicmimicryanegativeindicatorforprogressionfreesurvivaloflungadenocarcinomairrespectiveoffirstlinetreatmentandepithelialgrowthfactorreceptormutationstatus